Ascentage Pharma (AAPG) Q2 2026 earnings review
Strong YoY Top-Line Growth Overshadowed by Sequentially Stalling Revenue and Spiraling Costs
Ascentage Pharma’s H1 2026 results highlight a growing disconnect between commercial scale and expense management. While year-over-year product sales grew an impressive 33% to $41.6M (RMB 282.4M), sequential analysis reveals a stalling top-line—product revenue actually declined 1.4% from H2 2025 to H1 2026. Despite this sequential revenue plateau, Selling & Distribution (S&D) and R&D expenses continued accelerating, driving a massive 38% YoY widening of the net loss to $120.4M (RMB 817.0M). The 'dual-engine' commercial strategy in China is driving hospital penetration, but the aggressive cash burn requires close monitoring as the company pushes toward global registrational trial readouts.
🐂 Bull Case
The company's commercial execution in China remains strong YoY. Olverembatinib is now on formulary at 394 hospitals (up 34% YoY), and Lisaftoclax has rapidly secured 60 hospital formularies.
Nine registrational Phase III clinical trials are advancing worldwide, including four cleared by the FDA/EMA. Execution on enrollment for POLARIS and GLORA programs lays the groundwork for 2027 NDA targets.
🐻 Bear Case
The transition from H2 2025 to H1 2026 shows zero top-line product growth, raising questions about whether the initial post-NRDL sales burst has saturated early-adopter demand.
Selling and distribution expenses surged 64% YoY to support Lisaftoclax. When S&D and administrative costs total roughly 120% of product revenue, the path to commercial profitability looks highly prolonged.
⚖️ Verdict: 🔴
Bearish. While the year-over-year revenue growth makes for good press release headlines, the sequential stagnation in product sales coupled with rapidly accelerating cash burn presents a fragile financial profile heavily reliant on future capital raises or milestone payments.
Key Themes
Sequential Revenue Stagnation Contradicts Growth Narrative
Management continues to tout the 'dual-engine commercial ramp', emphasizing 33% YoY product sales growth. However, calculating the sequential half-over-half performance reveals a starkly different reality: product revenue went from RMB 286.4M in H2 2025 to RMB 282.4M in H1 2026. This indicates Decelerating/Stable near-term demand. The inability to grow the top-line sequentially while aggressively expanding the commercial team is a major red flag.
Accelerating Cash Burn Profile
Total operating expenses are Accelerating significantly faster than revenue. R&D increased 32.0% YoY (RMB 697.5M), while Selling & Distribution costs surged 64.3% YoY (RMB 226.4M). Consequently, the net operating cash outflow was RMB 581.2M for the half-year. While the company holds US$279.4M in cash, this represents a 23.3% reduction in just six months, pressuring the 'runway through 2027' narrative.
Expanding Direct-to-Patient and Hospital Access
Despite sequential sales weakness, foundational commercial access is expanding. Olverembatinib's footprint reached 879 DTP pharmacies/hospitals (up 12% YoY), driven directly by a 34% increase in hospital formulary inclusion to 394 sites. Lisaftoclax is following a similar playbook, already achieving 415 DTP/hospital placements.
APG-3288 PROTAC Represents Next-Gen Catalyst
Ascentage secured IND clearances in both the US and China for APG-3288, a highly selective BTK degrader. As traditional BTK inhibitors face resistance (e.g., C481S mutation), this proteolysis-targeting chimera (PROTAC) technology could offer a distinct pipeline driver, especially when potentially combined with Lisaftoclax to create a proprietary all-oral, fixed-duration regimen.
Macro Factor: Pivoting to NRDL for Lisaftoclax
With Olverembatinib already benefiting from National Reimbursement Drug List (NRDL) inclusion, management explicitly confirmed plans to pursue NRDL inclusion for Lisaftoclax in 2026. While NRDL listing generally triggers severe price cuts (often 60-80%), it is the mandatory macro gateway for driving volume in the Chinese market and will be critical to overcoming the current sequential revenue plateau.
Global Commercial Buildout Underway
The appointment of Jim Ziegler as Chief Commercial Officer and Dr. Faiçal Miyara as Chief Business Officer signals an Accelerating transition toward a global footprint. The company is actively splitting its focus between defending Chinese market share and establishing its own US commercial infrastructure ahead of potential 2027 global NDA filings.
Intense Global Hematology Competition
Ascentage is fighting well-capitalized incumbents. The need to dramatically ramp S&D expenses reflects the fierce defense required against competing assets like Asciminib and domestic entrants like Sonrotoclax. The inability to lean on price increases places the entire burden of growth on clinical differentiation and aggressive marketing volume.
Other KPIs
Accelerating. Up 32.0% YoY on a constant currency basis, driven by the expanding scope of the nine global registrational Phase III clinical trials, specifically POLARIS and GLORA cohorts.
Decelerating. Down 23.3% from US$353.2M at the end of 2025. This rapid depletion underscores the heavy capital requirements of simultaneous global phase III trials and a domestic commercial launch.
Guidance
Stable. The company plans to initiate new clinical studies to confirm Lisaftoclax's potential to overcome resistance in patients failing venetoclax treatment.
Accelerating effort to secure Chinese state reimbursement in 2026, which is crucial for unlocking mass-market volumes to offset inevitable price cuts.
Key Questions
Sequential Revenue Stagnation
Product revenue was essentially flat from H2 2025 to H1 2026 despite a 64% YoY increase in S&D spend in H1. What is driving this apparent plateau, and are we seeing peak early-adopter saturation in China?
Takeda Option Catalyst
With the Takeda opt-in for Olverembatinib serving as a major potential global catalyst, what clinical or regulatory milestones in the next 12 months are most likely to trigger a decision?
S&D Expense Peak
At what point does management expect S&D expenses to normalize as a percentage of revenue, and what is the target margin profile for the commercial business in China once fully scaled?
Cash Runway Visibility
Given the US$73.8M cash burn in the first six months of the year, does management still stand by its prior guidance that current capitalization will fund operations through the end of 2027 without a dilutive raise?